Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2009 1
2011 3
2012 1
2015 2
2016 1
2017 1
2018 3
2021 1
2022 3
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study.
Straatmijer T, Biemans VBC, Visschedijk M, Hoentjen F, de Vries A, van Bodegraven AA, Bodelier A, de Boer NKH, Dijkstra G, Festen N, Horjus C, Jansen JM, Jharap B, Mares W, van Schaik FDM, Ponsioen C, Romkens T, Srivastava N, van der Voorn MMPJA, West R, van der Woude J, Wolvers MDJ, Pierik M, van der Meulen-de Jong AE, Duijvestein M; Initiative on Crohn and Colitis. Straatmijer T, et al. Among authors: mares w. Clin Gastroenterol Hepatol. 2023 Jan;21(1):182-191.e2. doi: 10.1016/j.cgh.2022.04.038. Epub 2022 May 26. Clin Gastroenterol Hepatol. 2023. PMID: 35644343 Free article.
Therapeutic drug monitoring of methotrexate in patients with Crohn's disease.
van de Meeberg MM, Fidder HH, Oldenburg B, Sundaresan J, Struys EA, Montazeri NSM, Mares WGN, Mahmmod N, van Asseldonk DP, Lutgens MWMD, Kuyvenhoven JP, Rietdijk ST, Nissen LHC, Koehestanie P, de Boer NKH, de Jonge R, Bouma G, Bulatović Ćalasan M; Dutch Initiative on Crohn and Colitis (ICC). van de Meeberg MM, et al. Among authors: mares wgn. Aliment Pharmacol Ther. 2023 Dec;58(11-12):1151-1162. doi: 10.1111/apt.17719. Epub 2023 Sep 28. Aliment Pharmacol Ther. 2023. PMID: 37767910
Early Versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological Outcomes.
Vermeire S, Hanzel J, Löwenberg M, Ferrante M, Bossuyt P, Hoentjen F, Franchimont D, Palatka K, Peeters H, Mookhoek A, de Hertogh G, Molnár T, van Moerkercke W, Lobatón T, Clasquin E, Hulshoff MS, Baert F, D'Haens G; LOVE-UC study group. Vermeire S, et al. J Crohns Colitis. 2024 Apr 23;18(4):540-547. doi: 10.1093/ecco-jcc/jjad179. J Crohns Colitis. 2024. PMID: 37934813
Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease.
Mahmoud R, Savelkoul EHJ, Mares W, Goetgebuer R, Witteman BJM, de Koning DB, van Tuyl SAC, Minderhoud I, Lutgens MWMD, Akol-Simsek D, van Schaik FDM, Fidder HH, Jansen JM, van Boeckel PGA, Mahmmod N, Horjus-Talabur Horje CS, Römkens TEH, Colombel JF, Hoentjen F, Jharap B, Oldenburg B; Dutch Initiative on Crohn’s and Colitis (ICC) and the AWARE study group. Mahmoud R, et al. Among authors: mares w. Clin Gastroenterol Hepatol. 2023 Mar;21(3):750-760.e4. doi: 10.1016/j.cgh.2022.08.024. Epub 2022 Aug 31. Clin Gastroenterol Hepatol. 2023. PMID: 36055567 Free article.
Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease.
Ten Bokkel Huinink S, de Jong DC, Nieboer D, Thomassen D, Steyerberg EW, Dijkgraaf MGW, Bodelier AGL, West RL, Römkens TEH, Hoentjen F, Mallant RC, van Tuyl BAC, Mares WGN, Wolfhagen FHJ, Dijkstra G, Reijnders JGP, de Boer NK, Tan ACITL, van Boeckel PGA, Tack GJ, van Asseldonk DP, D'Haens GRAM, van der Woude CJ, Duijvestein M, de Vries AC. Ten Bokkel Huinink S, et al. Among authors: mares wgn. Eur J Gastroenterol Hepatol. 2022 Oct 1;34(10):983-992. doi: 10.1097/MEG.0000000000002403. Epub 2022 Aug 30. Eur J Gastroenterol Hepatol. 2022. PMID: 36062493
Healthy Cotwins Share Gut Microbiome Signatures With Their Inflammatory Bowel Disease Twins and Unrelated Patients.
Brand EC, Klaassen MAY, Gacesa R, Vich Vila A, Ghosh H, de Zoete MR, Boomsma DI, Hoentjen F, Horjus Talabur Horje CS, van de Meeberg PC, Willemsen G, Fu J, Wijmenga C, van Wijk F, Zhernakova A, Oldenburg B, Weersma RK; Dutch TWIN-IBD consortium and the Dutch Initiative on Crohn and Colitis. Brand EC, et al. Gastroenterology. 2021 May;160(6):1970-1985. doi: 10.1053/j.gastro.2021.01.030. Epub 2021 Jan 19. Gastroenterology. 2021. PMID: 33476671 Free article.
Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.
Wong DR, Coenen MJ, Derijks LJ, Vermeulen SH, van Marrewijk CJ, Klungel OH, Scheffer H, Franke B, Guchelaar HJ, de Jong DJ, Engels LG, Verbeek AL, Hooymans PM; TOPIC Recruitment Team. Wong DR, et al. Aliment Pharmacol Ther. 2017 Feb;45(3):391-402. doi: 10.1111/apt.13879. Epub 2016 Dec 12. Aliment Pharmacol Ther. 2017. PMID: 27943397 Free article. Clinical Trial.
Implementation of 'IBD-Specific Cognitive Behavioural Therapy' for Patients with Inflammatory Bowel Diseases with Poor Mental Quality of Life, Anxiety and Depression.
Bennebroek Evertsz' F, Bockting CL, Braamse A, van Dissel MNM, Duijvestein M, Kager LM, Kool M, Löwenberg M, Mares W, Nieuwkerk P, Sipkema HA, Young Z, Knoop H. Bennebroek Evertsz' F, et al. Among authors: mares w. J Clin Psychol Med Settings. 2024 Jun;31(2):258-278. doi: 10.1007/s10880-023-09996-8. Epub 2024 Jan 28. J Clin Psychol Med Settings. 2024. PMID: 38281306 Clinical Trial.
19 results